Actinium Pharmaceuticals, Inc. (ATNM) stock
ATNMNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 10/3081% below fair value
$1.35−0.14 (-9.40%)
Close on Nov 17, 2026Market cap $42.45MP/E 3.8Yield –
Actinium Pharmaceuticals price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Actinium Pharmaceuticals's price to sales ratio was 384.8× on Apr 30, 2026, against 74.7× a year earlier.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Apr 30, 2026 | 384.8× | +165.4 |
| 2023 | Apr 28, 2023 | 219.4× | −35.6 |
| 2022 | Dec 30, 2022 | 255.0× | – |
See a number that looks wrong?